Medication changes after switching from CONCERTA® brand methylphenidate HCl to a generic long-acting formulation: A retrospective database study

PloS One
Daniel FifeAnthony G Sena

Abstract

Observational studies of switching from branded to generic formulations of the same drug substance often lack appropriate comparators for the subjects who switched. Three generic formulations were deemed equivalent to Concerta: an authorized generic (AG) identical except for external packaging, and two other generics (EG). Compare the incidence of a combined endpoint (switching back to Concerta, changing the use of immediate release methylphenidate (MPH), stopping all long-acting methylphenidate, or starting a new medication) among people switched from Concerta to the AG versus the EG. Cohort study from the Truven CCAE database of people aged 6 to 65 diagnosed with ADHD, treated with Concerta, and switched to the EG or to the AG formulation. In the EG arm 24.6% and in the AG arm 19.7% of subjects switched back to Concerta. The proportion of subjects meeting the combined endpoint was 39.5% in the EG arm, 32.9% in the AG arm, a crude risk ratio of 1.20 (95% CI 0.94, 1.54). After adjustment by propensity score stratification, the adjusted odds ratio (OR) was 1.23 (95% CI 0.90, 1.70). In an unplanned analysis using a different method of adjustment, the adjusted OR was 1.00 (95% CI 0.69, 1.44). This study did not detect a difference...Continue Reading

Associated Clinical Trials

References

Aug 13, 1998·Journal of Abnormal Child Psychology·C K ConnersJ N Epstein
Dec 28, 2006·The Annals of Pharmacotherapy·Hillel HalkinNurit Friedman
Mar 18, 2011·Journal of Clinical Pharmacy and Therapeutics·A Helin-SalmivaaraR Huupponen
Aug 1, 2013·Statistics in Medicine·Martijn J SchuemieDavid Madigan
Jan 10, 2014·Science Translational Medicine·Slavenka Kam-HansenRami Burstein
Jan 13, 2015·Clinical and Translational Science·Elaine LarsonRachel Lally
Jul 2, 2015·The New England Journal of Medicine·Ted J Kaptchuk, Franklin G Miller

❮ Previous
Next ❯

Citations

Jul 28, 2018·Expert Opinion on Drug Safety·Jingjing QianRichard A Hansen
Oct 12, 2018·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Rachel E SobelRobert F Reynolds
Dec 5, 2019·Journal of Developmental and Behavioral Pediatrics : JDBP·Alison SchonwaldSarah S Nyp
Aug 19, 2018·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Joshua J GagneSarah K Dutcher
Apr 9, 2021·Journal of Clinical Pharmacy and Therapeutics·Justine AlderferT Joseph Mattingly

❮ Previous
Next ❯

Software Mentioned

CONCERTA

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.